The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Circulating tumor cells (CTCs) and LDH as prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing during or following docetaxel treated in the orteronel phase 3 ELM-PC 5 trial.
Howard I. Scher
Consultant or Advisory Role - Millennium
Karim Fizazi
Consultant or Advisory Role - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Dendreon; Ipsen; Janssen; Medivation; Millennium; Novartis; Sanofi
Connie Lee
Employment or Leadership Position - Takeda
David Maclean
Employment or Leadership Position - Takeda
Bindu Tejura
Employment or Leadership Position - Takeda
Stock Ownership - Takeda
Iain James Webb
Employment or Leadership Position - Takeda
Niels Geert Borgstein
Employment or Leadership Position - Takeda
Stock Ownership - Takeda
Robert Dreicer
Consultant or Advisory Role - Dendreon; Endo Pharmaceuticals; Janssen; Medivation; Millennium
Honoraria - Dendreon; Janssen
Research Funding - BIND Biosciences; Endo Pharmaceuticals; Millennium; Progenics